Healthcare provider profile · identity verified

Nayankumar Rameshbhai Patel, MD

Internal Medicine · PLANT CITY, FL · NPI 1164675369

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	200	39
Atorvastatin Calcium	Atorvastatin Calcium	163	39
Furosemide	Furosemide	134	49
Levothyroxine Sodium	Levothyroxine Sodium	121	15
Metoprolol Tartrate	Metoprolol Tartrate	114	39
Carvedilol	Carvedilol	91	24
Eliquis	Apixaban	79	24
Pantoprazole Sodium	Pantoprazole Sodium	76	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	73	12
Clopidogrel	Clopidogrel Bisulfate	68	20
Metoprolol Succinate	Metoprolol Succinate	63	28
Gabapentin	Gabapentin	60	14
Donepezil Hcl	Donepezil Hcl	59	11
Memantine Hcl	Memantine Hcl	54	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	53	15
Xarelto	Rivaroxaban	53	suppressed
Simvastatin	Simvastatin	50	suppressed
Potassium Chloride	Potassium Chloride	48	16
Enulose	Lactulose	47	suppressed
Latanoprost	Latanoprost	45	suppressed
Metformin Hcl	Metformin Hcl	43	12
Losartan Potassium	Losartan Potassium	42	20
Prednisone	Prednisone	42	42
Lisinopril	Lisinopril	40	17
Mirtazapine	Mirtazapine	40	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	37	suppressed
Methenamine Hippurate	Methenamine Hippurate	37	12
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Ondansetron Odt	Ondansetron	32	suppressed
Midodrine Hcl	Midodrine Hcl	30	14
Memantine Hcl Er	Memantine Hcl	28	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Famotidine	Famotidine	27	suppressed
Linzess	Linaclotide	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Divalproex Sodium	Divalproex Sodium	26	suppressed
Risperidone	Risperidone	26	suppressed
Novolog Flexpen	Insulin Aspart	25	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	23	suppressed
Cefuroxime	Cefuroxime Axetil	23	21
Meloxicam	Meloxicam	23	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	22	16
Sucralfate	Sucralfate	22	suppressed
Timolol Maleate	Timolol Maleate	22	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	20	suppressed
Finasteride	Finasteride	20	suppressed
Primidone	Primidone	20	suppressed
Spironolactone	Spironolactone	19	suppressed
Carbamazepine Er	Carbamazepine	17	suppressed
Neupro	Rotigotine	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	15	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	15	13
Trazodone Hcl	Trazodone Hcl	15	suppressed
Cefdinir	Cefdinir	14	14
Enalapril Maleate	Enalapril Maleate	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Restasis	Cyclosporine	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Budesonide	Budesonide	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Allopurinol	Allopurinol	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Aripiprazole	Aripiprazole	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Lubiprostone	Lubiprostone	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	11	suppressed
Clonidine	Clonidine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error